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Background
Replication-incompetent adenovirus vectors have
shown promise as vaccine candidates. We are develop-
ing replication-competent adenovirus vectors to
increase antigen expression and duration and to facili-
tate mucosal routes of vaccine delivery. We have devel-
oped replication-competent Ad5 (rcAd5) and Ad26
(rcAd26) based vectors, tested their growth in human
and simian cell lines, and determined the dynamics of
virus shedding after inoculation of rhesus monkeys.
Methods
Replication-competent Ad5 and Ad26 vectors were pro-
duced by adding the E1 region back into the vector. To
facilitate rcAd5 growth in rhesus monkey cells, 2 host
range mutations were also introduced into the DNA bind-
ing protein. The growth of rcAd5 and rcAd26 was tested
in human (Per55K, 293, and A549) and simian (CV-1 and
Cos7) cell lines. In addition, rcAd5 was administered intra-
nasally to rhesus monkeys, and the kinetics of viral shed-
ding was determined by qPCR on nasal, oral, and rectal
swabs, and serum.
Results
As expected, replication-incompetent Ad5 and Ad26 grew
in the E1-complementing cell lines Per55K and 293, but
not in A549 or CV-1 cells. In contrast, rcAd5 and rcAd26
grew in all human and simian cell lines tested, although
rcAd26 growth was suboptimal in simian cells. After intra-
nasal inoculation of rhesus monkeys, rcAd5 viral
sequences could be detected by qPCR in nasal swabs for
5 weeks post-inoculation.
Conclusion
Replication-competent Ad vectors can be produced effi-
ciently by the re-introduction of E1 into standard repli-
cation-incompetent vector backbones. However, the
extent of replication in simian cells appears to vary
based on Ad serotype. Future studies will compare the
immunogenicity of replication-competent vs. replica-
tion-incompetent Ad vectors.
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